Generic regulatory convergence project extended to more products
This article was originally published in Scrip
Executive Summary
The European Medicines Agency is to begin sharing its assessment reports on generic medicines with selected non-EU regulatory agencies as part of a drive to improve the efficiency of review processes and make it possible to synchronize marketing authorizations across different jurisdictions.
You may also be interested in...
COVID-19: Gilead To Fill Remdesivir Supply Gap In EU
As the US firm prepares to ramp up production of the antiviral for use in coronavirus patients, a debate is growing over whether changes could be made to EU rules that prevent the importation of generic drugs produced under a compulsory license.
Regulators Want Tough Criteria For COVID-19 Vaccine Efficacy Trials
The International Coalition of Medicines Regulatory Authorities have sketched out the criteria that should be met before candidate coronavirus vaccines can proceed into late-stage trials, and agreed on how to design the studies and who should be included.
Five Compounds To Be Tested In UK’s TACTIC Coronavirus Study
The UK government has awarded “urgent public health status” to a clinical trial program that will test one investigational product and four existing drugs in an effort to quickly find new treatments for patients hospitalized with serious COVID-19 infection.
Need a specific report? 1000+ reports available
Buy Reports